Case ID: f-appx_424/html/0952-02.html
Source: Caselaw Access Project
Author: {"author": "", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION. Eurand, Inc., Cephalon, Inc., and Anesta AG, Plaintiffs-Appellees, v. Mylan Pharmaceuticals Inc. and Mylan Inc., Defendants-Appellants.
    No. 2011-1399.
    United States Court of Appeals, Federal Circuit.
    May 25, 2011.
    William J. Marsden Jr., Fish & Richardson, P.C., Wilmington, DE, for PlaintiffsAppellees.
    James H. Wallace Jr., Kevin P. Anderson, Robert J. Scheffel, Mark A. Pacella, Brian H. Pandya, Matthew J. Dowd, Wiley Rein LLP, Washington, DC, for Defendants-Appellants.
    
      Before GAJARSA, Circuit Judge.
   ORDER

ON MOTION

Mylan Pharmaceuticals Inc. et al. submit a motion for a stay, pending appeal, of the injunction entered by the United States District Court for the District of Delaware on May 24, 2011. Mylan also requests an immediate stay of the injunction pending disposition of its motion for a stay, pending appeal and for expedited briefing of the stay motion.

Upon consideration thereof,

It Is Ordered That:

(1) Eurand, Inc. et al. are directed to respond no later, than 12:00 p.m. on May 31, 2011.

(2) Mylan’s request for an immediate stay is granted to the extent that the injunction is temporarily stayed pending the court’s receipt of the response and the court’s consideration of the papers submitted.